.jpeg)
2026-06-08 02:54:25
Discover the latest 2026 data on Trametinib (Mekinist) plus Dabrafenib for BRAF V600-mutant tumors. This article covers efficacy, global cost insights, dosing, and side effect management for patients and caregivers worldwide.
2026-06-05 06:44:46
This article explains why mitotane, a drug for adrenocortical carcinoma, must not be stopped abruptly, and outlines a safe tapering protocol under medical supervision, including monitoring and management.
2026-06-05 06:17:52
Pemigatinib delivers breakthrough efficacy for patients with advanced cholangiocarcinoma harboring FGFR2 fusions/rearrangements, showing an objective response rate of 35.5% and a median overall survival of 21.1 months in a key study.
2026-06-05 06:10:25
Erlotinib is an oral EGFR tyrosine kinase inhibitor that works by precisely blocking the growth signaling pathways in non-small cell lung cancer cells harboring specific EGFR gene mutations, thereby inhibiting tumor progression.
2026-06-05 05:52:29
Tofacitinib is an oral JAK inhibitor that suppresses inflammation by blocking cytokine signaling pathways. It is approved for the treatment of various immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
2026-06-05 05:46:25
Tucatinib, a highly selective HER2 tyrosine kinase inhibitor, is demonstrating key value in treating HER2-positive breast cancer with brain metastases and colorectal cancer. Its precise mechanism and favorable tolerability are advancing HER2-targeted therapy.
2026-06-05 05:25:02
In May 2026, the U.S. FDA approved atezolizumab for the adjuvant treatment of adult patients with muscle-invasive bladder cancer who are found to be circulating tumor DNA molecular residual disease positive following surgery. This approval marks the official entry of "ctDNA-guided immunotherapy" into clinical practice for bladder cancer.
2026-06-04 04:43:32
This article systematically introduces the drug classification, core mechanism of action, clinical significance of the targeted pathway and global approval status of Omaveloxolone, and details the pharmacological characteristics and therapeutic value of this first disease-modifying therapy approved for Friedreich's ataxia.
2026-06-04 04:33:17
This article provides detailed information on Ixekizumab (brand name Taltz), including its dosage forms and strengths, standard dosing regimens for psoriasis, psoriatic arthritis and Crohn's disease, injection techniques, storage conditions, missed dose management and treatment duration recommendations, offering comprehensive reference for patients and healthcare providers.
2026-06-04 03:40:01
This article systematically explains the acquired resistance phenomenon of Garsorasib, a KRAS G12C covalent inhibitor, and details common resistance mechanisms, standardized diagnostic procedures, individualized subsequent treatment strategies based on different resistance mechanisms, cutting-edge combination regimens and clinical trial opportunities, providing comprehensive reference for clinical management and patient treatment decisions.
2026-06-04 03:20:48
Belzutifan, the first-in-class HIF-2α inhibitor, revolutionizes treatment for VHL syndrome-associated tumors and advanced renal cell carcinoma (RCC). This guide provides comprehensive insights into its clinical application, dosing strategies, special population considerations, safety monitoring, and contraindications. Essential for urologists, neurosurgeons, and endocrinologists to optimize outcomes and precision care in managing complex oncology cases.
2026-06-04 02:35:34
Discover the latest advancements in cancer drug development, innovative targeted therapies, and cutting-edge technologies like proton therapy, bringing new hope to patients with pancreatic, bile duct, and head and neck cancers.
